Silver Book Fact

Close to one third of all drugs currently in the biopharmaceutical pipeline are for cancer, with around 5,500 potential first-in-class cancer medicines in development.

Innovation in the Biopharmaceutical Pipeline: A multidimensional view. http://www.phrma.org/sites/default/files/pdf/2013innovationinthebiopharmaceuticalpipeline-analysisgroupfinal.pdf. Published 2013

Reference

Title
Innovation in the Biopharmaceutical Pipeline: A multidimensional view.
Publisher
Analysis Group
Publication Date
Published 2013
Authors
Long, G and J Works
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Low dose CT screening for lung cancer costs less than $200 per person, and surgery for stage I lung cancer is less than 1/2 the cost of late-stage treatment.  
  • In the U.S., new cancer drugs have increased life expectancy at birth by 10.7%.  
  • After one year, 73 percent of non-small-cell lung cancer patients with the EGFR genetic mutation who were treated with a tyrosine kinase inhibitor had survived, compared to 15 percent who…  
  • Medicines in Devlopment for Cancer, 2008  
  • “Knowing that his disease had a high cure rate, Ben Dacus felt a sense of security at a time of great uncertainty. In 1988 he was diagnosed with Hodgkin’s disease. Strangely…